Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2006; 12(8): 1255-1260
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1255
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1255
Table 1 Distribution of HBV, HCV and HIV markers (tested with AxSYMTM) in all individuals referred to the laboratory
| HBsAg neganti-HBs neg | Anti-HBc posHBsAg posAnti-HBs neg | HBsAg neganti-HBs pos | Anti-HBc neg | |
| Study period | 82 mo (6/96-4/03) | 12 mo (1/03-12/03) | ||
| n (% of anti-HBc pos) | 552 (18.4 %) | 412 (13.7 %) | 2040 (67.9 %) | 4398 |
| Male/female (ratio) | 370/180 (2.06 : 1) | 251/145 (1.73 : 1) | 1185/851 (1.39 : 1) | 2631/1766 (1.49 : 1) |
| Age (yr; mean±SD) | 58.5 ± 16.5 | 42.8 ± 17.4 | 57.4 ± 16.7 | 50.4 ± 19.6 |
| Anti-HCV pos/n tested (%) | 112/550 (20.36 %) | 20/323 (6.19 %) | 144/1983 (7.26 %) | 95/4285 (2.22 %) |
| Anti-HIV pos/n tested (%) | 17/540 (3.15 %) | 8/206 (3.88 %) | 23/1571 (1.46 %) | 7/3768 (0.19 %) |
Table 2 Clinical data in individuals with reactivity to "anti-HBc alone"
| HBV-DNA-PCR in serum1 | |||
| Positive | Negative | ||
| n | 44 | 501 | |
| Males/females2 | 27/17 | 336/163 | |
| Age (mean ± SD) | 57.2 ± 18.6 | 58.5 ± 16.2 | |
| ALT2 | Normal | 23/35 (65.7%) | 251/402 (62.4%) |
| ≤Twofold increase | 7/35 (20.0%) | 81/402 (20.1%) | |
| > Twofold increase | 5/35 (14.3%) | 70/402 (17.4%) | |
| Liver ultrasound2 | no pathological findings | 5/11 (45.5%) | 112/204 (54.9%) |
| Steatosis | 5/11 (45.5%) | 63/204 (30.9%) | |
| Cirrhosis | 0/11 | 20/204 (9.8%) | |
| Carcinoma | 1/11 (9.1%) | 9/204 (4.4%) | |
| Liver histology2 | No pathological findings | 0/2 | 5/42 (11.9%) |
| Viral inflammation | 1/2 (50%) | 7/42 (16.7%) | |
| Steatosis | 0 /2 | 3/42 (7.1%) | |
| Cirrhosis | 0 /2 | 17/42 (40.5%) | |
| Carcinoma | 1/2 (50%) | 10/42 (23.8%) | |
| Anti-HBs titer (IU/L) | 1.9 ± 2.5 | 2.6 ± 3.0 | |
| Anti-HBe pos/n tested | 6/9 (66.7%) | 53/138 (38.4%) | |
| Anti-HCV pos/n tested | 7/44 (15.9%) | 103/500 (20.6%) | |
| Anti-HIV pos/n tested | 0/43 (0 %) | 17/491 (3.5%) | |
Table 3 Clinical data in “anti-HBc alone” individuals and anti-HCV status
| Anti-HCV | P-value | |||
| Positive | Negative | |||
| Sex | Males | 76 | 290 | NS2 |
| Females | 36 | 141 | ||
| ALT1 | Normal | 31 | 244 | < 0.001 |
| ≤ Twofold increase | 20 | 67 | ||
| > Twofold increase | 48 | 29 | ||
| Liver ultrasound1 | No pathological findings | 27 | 89 | 0.03 |
| Steatosis | 25 | 43 | ||
| Cirrhosis | 11 | 9 | ||
| Carcinoma | 6 | 4 | ||
| Liver histology1 | No pathological findings | 0 | 0 | < 0.001 |
| Viral inflammation | 8 | 0 | ||
| Steatosis | 2 | 1 | ||
| Cirrhosis | 12 | 4 | ||
| Carcinoma | 6 | 4 | ||
- Citation: Knöll A, Hartmann A, Hamoshi H, Weislmaier K, Jilg W. Serological pattern “anti-HBc alone”: Characterization of 552 individuals and clinical significance. World J Gastroenterol 2006; 12(8): 1255-1260
- URL: https://www.wjgnet.com/1007-9327/full/v12/i8/1255.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i8.1255